iCAD (NASDAQ:ICAD) Stock Crosses Above 200-Day Moving Average – Here’s What Happened

iCAD, Inc. (NASDAQ:ICAD) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.61 and traded as high as $2.06. iCAD shares last traded at $1.96, with a volume of 197,827 shares traded.

Wall Street Analyst Weigh In

Separately, StockNews.com raised iCAD from a “sell” rating to a “hold” rating in a report on Thursday, November 21st.

iCAD Stock Performance

The firm has a market cap of $50.43 million, a price-to-earnings ratio of -14.62 and a beta of 1.40. The business’s 50 day moving average price is $1.83 and its 200 day moving average price is $1.61.

Institutional Investors Weigh In On iCAD

An institutional investor recently bought a new position in iCAD stock. Essex LLC acquired a new stake in iCAD, Inc. (NASDAQ:ICAD) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 137,963 shares of the technology company’s stock, valued at approximately $216,000. Essex LLC owned 0.52% of iCAD at the end of the most recent quarter. 24.61% of the stock is currently owned by hedge funds and other institutional investors.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.